scispace - formally typeset
A

Andreas Wicki

Researcher at University of Basel

Publications -  28
Citations -  2018

Andreas Wicki is an academic researcher from University of Basel. The author has contributed to research in topics: Cancer & Urban climate. The author has an hindex of 17, co-authored 28 publications receiving 1851 citations. Previous affiliations of Andreas Wicki include University Hospital of Basel.

Papers
More filters
Journal ArticleDOI

Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton

TL;DR: Results indicate that podoplanin promotes tumor cell invasion in vitro and in vivo and induces collective cell migration by filopodia formation via the downregulation of the activities of small Rho family GTPases.
Journal ArticleDOI

The potential role of podoplanin in tumour invasion

TL;DR: This work revisits the mechanism of podoplanin-mediated tumour invasion and compares molecular pathways leading to single and collective cell invasion, and discusses novel distinct concepts of tumour cell invasion.
Journal ArticleDOI

NCAM‐induced focal adhesion assembly: a functional switch upon loss of E‐cadherin

TL;DR: A mechanistic link is established between the loss of E‐cadherin expression, NCAM function, focal adhesion assembly and cell migration and invasion in EMT.
Journal Article

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

TL;DR: The high density of GLP-1 receptors in insulinomas as well as the high specific uptake of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 in the tumor of Rip1Tag2 mice indicate that targeting of GLp-1 receptor in insulinoma may become a useful imaging method to localize insulinomas in patients, either preoperatively or intraoperatively.

Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting

TL;DR: In this article, a newly designed exendin-4-DTPA conjugate was used for GLP-1 receptor targeting in human insulinomas and gastrinomas using receptor-avid radioligands.